About the Authors

Lisa Zimmer

lisa.zimmer@uk-essen.de

Affiliation Department of Dermatology, University Hospital, University Duisburg-Essen, Essen, Germany

Julia Vaubel

Affiliation Department of Dermatology, University Hospital, University Duisburg-Essen, Essen, Germany

Peter Mohr

Affiliation Department of Dermatology, Buxtehude, Germany

Axel Hauschild

Affiliation University Department of Dermatology, Kiel, Germany

Jochen Utikal

Affiliations Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany, Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany

Jan Simon

Affiliation University Department of Dermatology, Leipzig, Germany

Claus Garbe

Affiliation University Department of Dermatology, Tübingen, Germany

Rudolf Herbst

Affiliation Department of Dermatology, Erfurt, Germany

Alexander Enk

Affiliation Department of Dermatology, University Hospital, Ruprecht-Karl University of Heidelberg, Heidelberg, Germany

Eckhart Kämpgen

Affiliation Department of Dermatology, University Hospital, Erlangen, Germany

Elisabeth Livingstone

Affiliation Department of Dermatology, University Hospital, University Duisburg-Essen, Essen, Germany

Leonie Bluhm

Affiliation Department of Dermatology, Buxtehude, Germany

Rainer Rompel

Affiliation Department of Dermatology, Kassel, Germany

Klaus G. Griewank

Affiliation Department of Dermatology, University Hospital, University Duisburg-Essen, Essen, Germany

Michael Fluck

Affiliation Department of Dermatology Hornheide, Münster, Germany

Bastian Schilling

Affiliation Department of Dermatology, University Hospital, University Duisburg-Essen, Essen, Germany

Dirk Schadendorf

Affiliation Department of Dermatology, University Hospital, University Duisburg-Essen, Essen, Germany

Competing Interests

I have read the journal’s policy and the authors of this manuscript have the following competing interests: Consultancy: LZ (Roche, Bristol-Myers Squibb, MSD Sharp and Dohme); JV (Roche); AH (Amgen, Bristol-Myers Squibb, Roche, EISAI, Celgene, GlaxoSmithKline, MedImmune, MelaScience, Merck Serono, MSD Sharp and Dohme, Novartis, Oncosec); RH (Bristol-Myers Squibb, GlaxoSmithKline, Merck Serono, Roche); AE (Biotest, Bristol-Myers Squibb, MSD Sharp and Dohme, Allergika); EL (Bristol-Myers Squibb, Boehringer-Ingelheim Pharma); DS (Bristol-Myers Squibb, Roche, Novartis, Amgen, GlaxoSmithKline); Board membership: PM (Bristol-Myers Squibb, Roche, MSD Sharp and Dohme, GlaxoSmithKline, Novartis, Merck); DS (Bristol-Myers Squibb, Roche, Novartis, Merck, Amgen, GlaxoSmithKline) Research grants: PM (Merck); AH (Amgen, Bristol-Myers Squibb, Roche, EISAI, Celgene, GlaxoSmithKline, MelaScience, Merck Serono, MSD Sharp and Dohme, Novartis, Oncosec); CG (Roche, Bristol-Myers Squibb, GlaxoSmithKline); AE (Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe); DS (Merck); Travel grants and honoraria for speaking or participation at meetings: LZ (Roche, Bristol-Myers Squibb, MSD Sharp and Dohme, GlaxoSmithKline, Novartis, Merck Serono, Teva), JV (Roche, Bristol-Myers Squibb, MSD Sharp and Dohme, GlaxoSmithKline, Novartis, Merck, Boehringer-Ingelheim Pharma, Galderma, Cephalon, Teva, Amgen); PM (Bristol-Myers Squibb, Roche, MSD Sharp and Dohme, GlaxoSmithKline, Novartis, Merck); AH (Amgen, Bristol-Myers Squibb, Roche, EISAI, Celgene, GlaxoSmithKline, MedImmune, MelaScience, Merck Serono, MSD Sharp and Dohme, Novartis, Oncosec); JU (Roche, Bristol-Myers Squibb, Roche, GlaxoSmithKline, MSD Sharp and Dohme, Leo Pharma); CG (Amgen, Roche, Bristol-Myers Squibb, GlaxoSmithKline, MSD Sharp and Dohme, Novartis); RH (Bristol-Myers Squibb, GlaxoSmithKline, Merck Serono, Roche); AE (Biotest, Bristol-Myers Squibb, MSD Sharp and Dohme, Janssen-Cilag, Roche, Allergika); EL (Bristol-Myers Squibb, Roche, Amgen, Boehringer-Ingelheim Pharma, MSD Sharp and Dohme, Merck); LB (Roche, Bristol-Myers Squibb, MSD Sharp and Dohme); MF (Bristol-Myers Squibb); BS (Bristol-Myers Squibb); DS (Bristol-Myers Squibb, Roche, Novartis, Merck, Amgen, GlaxoSmithKline); Relationship (paid or unpaid) with organizations and funding bodies including: CG (European Association of Dermatooncology); AE (Deutsche Forschungsgemeinschaft); Nongovernmental organizations, research institutions, or charities: CG (Deutsche Dermatologische Gesellschaft); AE (European Society for Dermatological Research). This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: DS LZ. Performed the experiments: LZ JV PM AH JU JS CG RH AE EK EL LB RR KGG MF BS DS. Analyzed the data: LZ JV PM AH JU JS CG RH AE EK EL LB RR KGG MF BS DS. Contributed reagents/materials/analysis tools: LZ JV PM AH JU JS CG RH AE EK EL LB RR KGG MF BS DS. Wrote the paper: LZ JV PM AH JU JS CG RH AE EK EL LB RR KGG MF BS DS.